Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review.
Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review.
复制标题
肠道微生物代谢物丁酸酯及其在炎症性肠病中的治疗作用：文献综述。
DOI：
10.3390/nu15102275
复制
发表时间：
2023-05-11
期刊：
影响因子：
5.9
通讯作者：
Shi XZ
中科院分区：
文献类型：
--
作者：
Recharla N;Geesala R;Shi XZ
背景和目的：炎症性肠病（IBD），包括克罗恩病和溃疡性结肠炎，是一种慢性炎症性疾病，其特征是异常的免疫反应和胃肠道屏障功能受损。IBD与结肠中肠道微生物群及其代谢物的改变有关。丁酸盐是肠道微生物代谢产物，在调节免疫功能、上皮屏障功能和肠道稳态中起着至关重要的作用。本文就丁酸盐的合成、代谢及其在维持肠道内环境稳定中的作用机制作一综述，并探讨丁酸盐在IBD中的治疗意义。研究方法：我们使用丁酸盐、炎症、IBD、克罗恩病和溃疡性结肠炎等检索词通过PubMed、Web of Science和其他来源检索了截至2023年3月的文献。丁酸盐的治疗意义总结中包括患者的临床研究和IBD啮齿动物模型的临床前研究。结果：在过去的二十年中，研究表明丁酸盐对肠道免疫功能和上皮屏障功能的有益作用。大多数临床前和临床研究表明，丁酸盐口服补充剂在结肠炎动物模型和IBD患者中减轻炎症和维持缓解方面具有积极作用。然而，丁酸盐灌肠剂表现出混合效应。在动物模型和IBD患者中，发现产丁酸饮食，包括发芽的大麦食品和燕麦麸，增加粪便丁酸盐浓度并降低疾病活动指数。结论：目前的文献表明，丁酸盐是一种潜在的添加治疗，以减少炎症和维持IBD缓解。需要进一步的临床研究来确定丁酸盐单独给药是否是IBD的有效治疗方法。
Background and objective: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder characterized by aberrant immune responses and compromised barrier function in the gastrointestinal tract. IBD is associated with altered gut microbiota and their metabolites in the colon. Butyrate, a gut microbial metabolite, plays a crucial role in regulating immune function, epithelial barrier function, and intestinal homeostasis. In this review, we aim to present an overview of butyrate synthesis and metabolism and the mechanism of action of butyrate in maintaining intestinal homeostasis and to discuss the therapeutic implications of butyrate in IBD. Methods: We searched the literature up to March 2023 through PubMed, Web of Science, and other sources using search terms such as butyrate, inflammation, IBD, Crohn’s disease, and ulcerative colitis. Clinical studies in patients and preclinical studies in rodent models of IBD were included in the summary of the therapeutic implications of butyrate. Results: Research in the last two decades has shown the beneficial effects of butyrate on gut immune function and epithelial barrier function. Most of the preclinical and clinical studies have shown the positive effect of butyrate oral supplements in reducing inflammation and maintaining remission in colitis animal models and IBD patients. However, butyrate enema showed mixed effects. Butyrogenic diets, including germinated barley foodstuff and oat bran, are found to increase fecal butyrate concentrations and reduce the disease activity index in both animal models and IBD patients. Conclusions: The current literature suggests that butyrate is a potential add-on therapy to reduce inflammation and maintain IBD remission. Further clinical studies are needed to determine if butyrate administration alone is an effective therapeutic treatment for IBD.
登录
查看更多内容
影响因子：
5.2
作者：
De Preter, Vicky;Falony, Gwen;Verbeke, Kristin
通讯作者：
Verbeke, Kristin
影响因子：
2.8
作者：
Gholami, Mahdi;Ghasemi-Niri, Seyedeh Farnaz;Abdollahi, Mohammad
通讯作者：
Abdollahi, Mohammad
影响因子：
24.5
作者：
Breuer, RI;Soergel, KH;Rademaker, AW
通讯作者：
Rademaker, AW
影响因子：
13.6
作者：
Foti, M;Ricciardi-Castagnoli, P
通讯作者：
Ricciardi-Castagnoli, P
影响因子：
7.6
作者：
Di Sabatino, A;Morera, R;Corazza, GR
通讯作者：
Corazza, GR